1 2 3 4 5 6 9 17 24 32

SOTIO Presents Poster on CLAUDIO-01 Trial at ESMO Congress

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting a trial-in-progress poster at the European Society for Medical Oncology Congress taking place October 20-24, 2023 in Madrid, Spain. 


SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

  • SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
  • Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
  • Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.

SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa

  • Ongoing clinical trials of nanrilkefusp alfa will be discontinued due to insufficient efficacy;
  • SOTIO plans to explore combinations of nanrilkefusp alfa with other modalities;
  • SOTIO to continue to advance its immunocytokine platform including next-generation SOT201 program.